The Pax3 protein has two DNA binding domains, a Paired Domain (PD) 1 
INTRODUCTION
Pax3 is a member of a family of 9 transcription factors (1), defined by a DNA binding module, the Paired domain (PD) , that was first identified in the Drosophila protein Paired (Prd) (2) . Pax proteins play critical roles during normal embryonic development, and inactivating mutations cause major defects in development of skeleton, muscles, nervous system, eyes, kidneys, and the immune system (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Pax3 is expressed in developing somites, neural tube as well as neural crest cell derivatives and plays a role in the proliferation, migration and differentiation of cells involved in neurogenesis and myogenesis (13, 14) . The Pax3 mouse mutant (splotch, Sp) displays spina bifida and exencephaly, and lacks limb muscles; likewise, mutations in human PAX3 cause Waardenburg syndrome (WS), a condition characterized by 6 G42R mutation in the PD which abrogates DNA binding by the PD, but also impairs DNA binding by the HD. Deletion of helix2 of the PAI subdomain in the context of the Sp d mutation has been shown to restore HD DNA binding (36) . Studies in chimeric PAX3 proteins have shown that the PD can modulate DNA binding specificity and dimerization potential of heterologous HDs (37) . On the other hand, a mutant PAX3 variant from a WS patient bearing a mutation at position 53 of the HD (R53G) shows not only loss of DNA binding by the HD but also by the PD (38) . More recent biochemical studies by cysteine scanning mutagenesis, and sitespecific modification of single cysteine mutants with sulfhydryl reagents have shown that modification of a single cysteine in the PD (Cys82) disables DNA binding by the PD but also by the HD (39) . Conversely, modification of a single cysteine at position 263 of the HD (V263C) of the HD abrogates DNA binding by both domains (39) .
The mechanistic basis of this functional interdependence, including the protein subdomains involved, remains poorly understood but is likely to be relevant for target site selection by Pax3 in vivo. One plausible mechanism is that DNA binding by one or both of the DNA binding sites of Pax3 causes conformational changes at or near the other binding site to alter its properties. Thus, we wanted to get insight into the conformations adopted by the Pax3 protein when DNA-free and when bound to PD or HD targets. A number of physico-chemical approaches have been used to monitor the effect of substrate binding on protein conformation, including differential immunoreactivity with specific antibodies (40) , tryptophan fluorescence 7 fragments by epitope mapping with specific antibodies and/or peptide sequencing (53) . Another implementation of this method involves creating recombinant proteins bearing single heterologous protease cleavage sites (such as Factor Xa) inserted at pre-determined positions in individual mutants. Proteolytic products can be identified using antibodies against antigenic epitope also engineered at convenient positions. In this approach, conformational changes can be studied in a set of recombinant proteins which structural and functional integrity has been ascertained.
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MATERIALS AND METHODS
Mutagenesis. The construction of the pMT2 expression plasmid containing the entire protein-encoding region of wildtype Pax3 cDNA has been previously described (39) . This pMT2/Pax3 construct encodes for all 479 amino acids of the murine Q+ isoform of Pax3 (54) . Factor Xa cleavage sites (IE/DGR; see Table 1 ) were introduced at different positions in 9 fashion and were introduced in pMT2. Mutants Pax3Xa66, Pax3Xa172 and Pax3Xa189 were created by insertion mutagenesis. For this, pMT2/ Myc-Pax3-HA plasmid was digested with BsmI, XbaI or ClaI and single or multiple Xa cleavage sites were introduced using double stranded oligonucleotides with cohesive ends (Tables 1 and 3 ). These oligonucleotides have a sequence just long enough to encode for one or a few Xa protease sites when placed in frame with the rest of the Pax3 encoding region. For mutants Pax3Xa100 and Pax3Xa216, the Pax3 cDNA was modified to introduce unique KasI and AflII sites at nucleotide positions 595 and 940, respectively, using mutagenic primers listed in Table 3 . These modified Pax3 cDNAs were subcloned into the EcoRI site of pBluescript (lacks KasI, AflII sites), and one or several factor Xa sites were independently introduced at the KasI or AflII sites by insertion mutagenesis to create mutants Xa100(2), Xa100(4), Xa216(1) and Xa216(2) ( Tables 1 and 3) . In all cases, the presence of the factor Xa mutations and the integrity of the rest of the Pax3 sequences were verified by nucleotide sequencing. The accessibility of restriction sites used for cloning was verified by restriction enzyme fragmentation. Xa protease, ranging from 0 to 200ng Xa protease/ µg whole cell extract, were then added to the reaction mixture, and proteolytic cleavage was allowed to take place for 15 minutes at 20 o C. The reaction was stopped by addition of 10µl of Laemmli sample buffer. For both assays the proteolytic degradation products were separated by SDS-PAGE on 12% polyacrylamide gels, followed by transfer onto nitrocellulose membranes. Immunodetection of Pax3 products were carried out using anti-HA antibody followed by anti-Myc antibody as described above. Films were used to perform densitometry studies to quantify the amount of chemiluminescence using a Fuji LAS -1000. were independently converted to I(E/D)GR (Table I) to minimize adverse structural changes possibly impairing DNA binding. Targeted in this group of 6 mutants were helices 1 ( 1, Xa55), (Xa252) and the N-terminus of helix 3 (Xa259) of the HD (Table 1 , Fig. 1 ). Secondly, and to maximize accessibility to proteolytic cleavage, several solvent-exposed, and less conserved linker segments were also targeted for insertion of 1 or several Xa sites (Table 1 , Fig. 1 ).
Expression and Detection of

RESULTS
Construction of Pax3 Mutants Bearing Factor Xa Protease Cleavage Sites
Targeted in this group of 10 mutants were the linker separating helix 1 and 2 of the PD (Xa66, 1 and 2 sites), the segment linking the first and second HTH motifs of the PD (Xa100, 2 and 4 sites), and the fragment separating the PD and the HD (Xa172, 1 and 3 sites; Xa189, 1 and 2 sites; Xa216, 1 and 2 sites). Multiple Xa sites were inserted at individual locations not only to maximize accessibility to protease fragmentation, but also to provide validation of observed effects.
DNA Binding Properties of Pax3Xa Mutants
Wild type Pax3 along with the various Pax3Xa mutants were introduced in the pMT2 . DNA binding by the PD was examined using oligonucleotide probes P3OPT (55, 56) and P6CON (27) , previously shown to reveal binding determinants present in both the amino (PAI) and carboxy (RED) subdomains of the PD ( 
Accessibility of Inserted Xa Sites to Proteolytic Cleavage
The accessibility of the inserted factor Xa sites to proteolytic cleavage was investigated and assume a compact conformation under the conditions tested (Fig. 3) . In contrast, mutant Xa100(2) yielded the expected 44kDa C-terminal HA-immunoreactive cleavage product upon incubation with factor Xa (filled arrowhead , Fig. 4) ; The 44kDa HA fragment was abundant at the earliest time point tested (2 min) and digestion was largely completed by 10 mins. Similar rapid cleavage of Xa100 (2), as demonstrated by disappearance of the full length 55kDa protein, was verified by immunoblotting with the anti-cMyc antibody (Fig. 5 ) although the N-terminal 12kDa cMyc reactive digestion product was not retained on the gel. Increasing the number of Xa sites from 2 to 4 in mutant Xa100(4) produced similar outcome with even more rapid and more complete cleavage at the targeted site. Thus, cleavage at position 100 is specific in these mutants and strongly suggest that the linker separating the PAI and RED subdomains of the PD is solvent exposed and protease accessible. Analysis of mutants Xa216(1) and Xa216 (2) immediately upstream the HD is solvent exposed and accessible to protease cleavage (Fig. 3) .
Effect of DNA Binding on Protease Sensitivity of Pax3 Mutants Xa100 and Xa216
The effect of Pax3 binding to PD (P3OPT) and HD (P1/2, P2) target sequences on the conformation of each domain was analyzed by monitoring the effect of DNA binding on accessibility of Xa cleavage sites present in mutants Xa100 (PD) and Xa216 (HD). Also included in these experiments were WT Pax3, as well as Pax3-Xa mutants previously observed to be resistant to factor Xa cleavage in time course studies (supplementary data). Briefly, cell extracts expressing Pax3 proteins were incubated with or without target DNA, followed by addition of factor Xa and detection of HA (Fig. 4) and cMyc ( Fig. 5 ) immunoreactive cleavage products appearing over time. The extent of protection from proteolytic fragmentation was further quantitated after densitometry of the immunoblots and is expressed as the fraction of intact full length Pax3 remaining following 20 minutes of incubation with factor Xa (Fig. 4B , 5B). For the WT Pax3, binding to PD or HD target sequences had no effect on digestion profiles, as expected, (Fig. 4) and anti-cMyc antibodies (Fig. 5) were in complete agreement (Fig. 4B , 5B).
Together, results from Xa100 and Xa216 are remarkably similar and suggest that DNA binding at either the PD or HD causes a conformational change at both sites. This change appears to reduce the amount of solvent exposed area in the protein, suggesting a more compact conformation of the DNA-bound protein.
Specificity of the protective effect of PD and HD target sequences on accessibility of the Xa sites in Xa100 and Xa216 mutants was investigated in dose-response studies. In these experiments, the Pax3 mutants were incubated with PD or HD oligonucleotide probes and DNAPax3 complexes were allowed to form; following this, increasing amounts of factor Xa protease was added to the reaction mixture which was further incubated for 15 minutes, and the appearance of specific proteolytic cleavages products was monitored by SDS-PAGE and immunoblotting with the anti-HA antibody (Fig. 6A) . In these studies, 2 additional control probes were tested to further validate the specificity of the DNA effect observed in time course studies: a second, independently derived PD oligonucleotide P6CON, and a PD and HD nonspecific oligo which was used as a negative control. Typical immunoblots are shown in Fig. 6A , and quantitation of the protective effects of the DNA probes by densitometry is shown in Fig. 6B (% of uncleaved Pax3 at concentration indicated by arrow in Fig. 6A ). These experiments showed that incubation of mutants Xa100(2) and Xa216(2) with PD oligonucleotides P6CON
and P3OPT reduced sensitivity of both proteins to increasing doses of factor Xa. Likewise, incubation of both proteins with HD probes P1/2 and P2 similarly increased resistance to factor Xa fragmentation. The effect of the 2 PD probes and 2 HD probes on protease sensitivity was specific and not seen in control DNA-free conditions (data not shown), and upon incubation with a non-specific target sequence (Fig. 6A/B (38), and c) the fact that Pax proteins can bind DNA exclusively through their PAI subdomain (28). We note that mutations Xa55 and Xa71 in the PAI domain impaired DNA binding to PD oligos only, while the Xa66 mutant showed impaired DNA binding to both PD and HD sequences. This behavior is similar to WS1 mutants G48R/S and P50L (upstream helix 1 of PAI), respectively, and has been suggested to reflect functional interdependence of the PD and HD in DNA binding (38) . Interestingly, insertion of 2 or even 4 Xa sites in the linker joining the PAI to the RED (Xa100) had no effect on DNA binding; this linker is well conserved amongst Pax proteins, and sequences immediately downstream the insertion site make extensive phosphate and base-specific contacts in the minor groove of DNA (Fig. 1) . As expected, the 3 insertions (Xa172, Xa189, Xa216) in the poorly conserved linker joining the PD and the HD, including one within the octapeptide motif (Xa189) conserved in other Pax proteins (HSIDGILG; (57)), had no major impact on DNA binding of the corresponding mutants to PD and HD sites. With respect to the HD, 2 mutations inserted either downstream helix 2 (Xa252) or upstream the major DNA binding helix 3 (Xa259) appeared to either strongly diminish or abrogate monomeric or dimeric DNA binding to HD target sequences (Fig. 2) . Although this conclusion is supported by both the high degree of conservation of the targeted sequences in the Paired-type HDs of the Pax family ( Fig. 1) , and the fact that many WSI mutations map to the HD of Pax3 (38), our inability to express high levels of these mutants precluded a more detailed analysis.
Evaluating the accessibility of inserted Xa sites to protease cleavage can readily provide insight into the solvent exposure of the corresponding Pax3 sub-domains. Results of time course studies were very clear and showed that of the 7 sites in which insertions preserved DNA binding only 2, Xa 100 and Xa216, were readily accessible to proteolytic cleavage at the earliest time points of analysis (Fig. 4) . In agreement with the proposed structural model of the PD (Fig. 7A) , these results showed that the PAI to RED subdomain linker (Xa100 mutant) is clearly exposed to solvent. Although this domain is not believed to play a critical role in DNA binding, current structural models suggest that it is in close proximity to DNA (25) . In addition, alternative splicing of a glutamine residue at position 108 of Pax3/Pax7 is known to alter DNA binding specificity of the PD (54, 58) . Therefore, mutants Xa100 should be ideally suited to monitor . Protein-DNA complexes were formed using total COS7 cell extracts and were resolved on 6% acrylamide non-denaturing gels, as described in Materials and Methods. Table 2 ). The position and size, in kDa of the molecular mass markers are displayed as dashes on the left and numbers on the right, respectively. All immunoblots probed with anti-HA antibody including those of Figure S1 were scanned by densitometry (Fig. 4B ).
The intensity of the immunoreactive intact full length WT protein and of individual Pax3 (2) proteins (empty arrowheads), and of the major predicted, HA-immunoreactive product (filled arrowhead, see Table 2 ) are shown. (B). For quantifying the effect of DNA binding on accessibility of factor Xa cleavage sites in doseresponse studies, the immunoblots in (A) were scanned by densitometry. The intensity of the immunoreactive intact Xa100(2) and Xa216(2) full length proteins was determined in the absence of factor Xa, and after digestion with a factor Xa amount indicated by the arrow at the top of each immunoblot series. The amount of intact protein remaining after factor Xa digestion was determined for Xa100(2) (black) and Xa216(2) (gray) and for all DNA binding conditions and is expressed as the fraction of intact protein (expressed as a percentage). Xa sites identified as causing loss-of DNA binding (red), as having no effect on DNA binding and being either accessible (purple) or not (blue) to factor Xa protease fragmentation.
SUPPLEMENTARY FIGURE 1:
Accessibility to Protease Cleavage of Factor Xa sites inserted in Additional Pax3 Mutants:
Effect of DNA Binding. Results are shown as described in legend to Figure 4 .
SUPPLEMENTARY FIGURE 2:
Accessibility to Protease Cleavage of Factor Xa sites inserted in Additional Pax3 Mutants:
Effect of DNA Binding. Results are shown as described in legend to Figure 5 . Expected specific carboxy terminal proteolytic fragment (kD) detectable using anti-HA antibody. 
Xa100 (4) Xa172 (1) Xa172 (3) Xa189 (1) Xa189 (2) Xa216 (1) Xa216 (2) ATCCATAGAAGGTAGAGG d Oligonucleotide sequences used (double stranded) for insertion mutagenesis in the creation of the corresponding Xa mutants as listed in Table 2 . -------HA   HD Xa100 (4) Xa216 (1) Xa216 (2) no DNA P3OPT P1/2 P2 Xa100 (4) Xa172 (1) Xa172 (3) Xa189 (1) Xa189 (2) Xa216 ( Xa100 (4) Xa172 (1) Xa172 (3) Xa189 (1) Xa189 (2) Xa216 ( 
--R-RT-F---Q---LE--F-RT-YPD---RE-LA----L-EAR-QVWFSNRRA--R-----m-m-----------------------------------------M--MM--------------p------------------p-----p------------p----p---p-p-p---
GQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRYQETGSIRPGAIGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKF -----NQLGG-F-NGRPLP---R--IV--A--G-RPC-ISR-L-VS-GCVSKIL-R---TG---P--IGGSK------P-----I----------F-WEI---L-----------PS-S-I-R--R----------------mm------------------------------MMMM-MM---------------mmmm--m--------------------------------------------M---M--M--------pp----p-ppppp----p-----------ppp---p---pp--p-pp---p--------ppss-ss-pppp-------------------ppp-----------------
21.4
Figure S2
